BioSpectrum
the business of Bio & Health Sciences
ASIA EDITION

New FDA-Cleared Smart Heart Monitor Keeps the Cardiologist a Heartbeat Away

June 8, 2017 | News

Eko DUO is the first cardiac monitor to combine digital stethoscope and ECG technology for in-clinic and at-home monitoring, offering 28 million heart disease patients the ability to seamlessly send cardiac data to their physicians

Singapore - Eko Devices ("Eko"), a US based company dealing with mobile acoustic cardiac monitoring tools, has received FDA clearance to market its latest innovation, DUO – a combined digital stethoscope and electrocardiogram (ECG). The portable cardiac device was inspired by cardiologists' demand for more effective monitoring tools for heart disease – the leading cause of death in the United States.

The alliance of ECG and digital stethoscope technology into a compact, handheld device offers unprecedented insight into cardiac function. Physicians will use DUO as a cutting-edge screening tool or prescribe it to heart disease outpatients as the centerpiece of at-home health kits. The device wirelessly pairs with Eko's secure, HIPAA-compliant app, enabling remote monitoring and diagnosis by a clinician or specialist.

DUO represents a shift in the fight against heart disease, empowering patients to use familiar smart tools under the remote supervision of their physician to navigate complex medical conditions and, ultimately, reduce unnecessary hospital readmissions.

"Cardiology programs are looking for ways to deliver hospital-quality healthcare at home," said Dr. Ami Bhatt, Director of Outpatient Cardiology and the Adult Congenital Heart Disease Program at Massachusetts General Hospital. "The ability to capture digital heart sounds and an ECG expands our portfolio of mechanisms to remotely monitor the heart, and brings

diagnosis and opportunities for early intervention even further upstream. Robust toolkits for caring for patients in the community will hopefully lead to more appropriate healthcare utilization through continuous rather than episodic outpatient care."

Following its vision to improve cardiovascular care, Eko is also developing machine-learning algorithms that can be combined with DUO to automatically alert patients and their care teams of suspected decline in cardiac function.